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S160 Oral Presentationsphenotype as determined by FACS staining. The cells produced the
pro-inflammatory cytokines IL1b, IL6, IL17, IP10, IFNg and
TNFa as determined byMultiplex immuno-assay and the cytotoxins
perforin and granzyme B, all necessary for viral elimination.
The generation of HAdV specific T-cells from naive UCB cells in
response to 15-mer HAdV peptides seems an essential step in devel-
oping a more tailor-made adoptive therapy for HAdV infection for
recipients of UCB transplants.
1 Haveman,LM,BieringsM,LeggerE, et al.Novel pan-DR-bind-
ingT-cell epitopes of adenovirus induce pro-inflammatory cytokines
and chemokines in healthy donors. Int Immunol. 2006;18:1521-9.15
FLAGELLIN-TLR5 IMMUNE RESPONSE: A NOVEL MECHANISM TO RE-
DUCE GVHD IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION
Hossain, M.S.1, Gewirtz, A.T.2, Roback, J.D.2, Waller, E.K.1 1Emory
University, Atlanta, GA; 2Emory University, Atlanta, GA
Background: Immunosuppressive drugs are used to limit GvHD
but causes complications. To develop an alternative approach to
control GvHD, we tested the immunomodulatory immune proper-
ties of flagellin, a bacterial protein that agonistically binds with
TLR5.
Methods: We used established B6 to CB6F1 and B10.BR to B6 allo-
geneicHSCT recipients had both acute and chronicGvHD. 50 mg fla-
gellin administered i.p 3 hours before 11 Gy irradiation. 5 million (M)
T-cell depleted bone marrow (TCDBM) and 5 M splenocytes of con-
geneic donors were transplanted i.v. 24 hours later another dose of fla-
gellin were administered i.p. Control recipients were treated with
0.2 ml PBS i.p. HSCT mice were monitored every day for mortality.
Weight of individual mice was measured twice a week until 30 days
post transplant and once a week after that tomeasureGvHD. Immune
reconstitution was determined by measuring immune cells/organs and
infecting the recipients with 510E3 pfu MCMV i.p.
Results: Flagellin treated recipients of in B6 to F1 model survived
100% and gained weight to almost normal level within 66 days post
transplant.But the control groupsurvived80%andhadsignsof chronic
GvHD. Flagellin-treated recipients in B10 to B6 model had 15%
weight-loss and 33% transplant-related death by 132 days post trans-
plant versus had severe acute GvHD and 100% early post-transplant
mortality amongcontrolHSCTrecipients. Flagellin-treated recipients
in B6 to F1 model showed 100% chimerism with significantly higher
number of donor spleen- and BM-derived CD4+ and CD8 +T cells
per spleen inuntreated recipientscompared tocontrol recipientswithin
66 days post transplant. In the spleen CFSE labeled CD4 +T cells di-
vided faster in flagellin-treated recipients than the control recipients
and decreasing the number of CD4 +CD62L+ T cells within 4 days
post transplant. B6 to F1 recipients were infected with MCMV on
70+dayspost transplant.Controlmicediedwithinday10post infection
whereas flagellin-treated recipients recovered from MCMV infection
and had higher number anti-viral+ CD8 +T cells in their blood on
day 10 and 35 post infection. Increased numbers of
CD25+foxp3 +CD4+ regulatoryT cells were alsomeasured from their
thymus on day 35 post MCMV infection.
Conclusion: Flagellin treatment successfully controlled GvHD, en-
hances donor T-cell engraftment, had brisk and persistent cellular
immune responses in lymphoid organs to protect recipients from vi-
ral infection.16
FACTORS PREDICTING NEW-ONSET DIABETES MELLITUS AND META-
BOLIC SYNDROME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION:
IMPLICATION FOR EARLY PREVENTIVE INTERVENTION
Griffith, M.L.1, Misfeldt, A.A.1, Chen, H.2, Jagasia, M.3, Kassim, A.3,
Savani, B.N.3, Survant, M.1, Jagasia, S.M.1 1Vanderbilt University
Medical Center, Nashville, TN; 2Vanderbilt University Medical Center,
Nashville, TN; 3Vanderbilt University Medical Center, Nashville, TN
Background: Incidence and risk factors for post-transplant diabetes
mellitus (PTDM) and long-term development of metabolic syn-drome (MS) after allogeneic stem cell transplantation (allo-SCT)
are not well defined.We conducted a prospective study of 84 patients
(pts) undergoing allo-SCT with cyclosporine-based graft-versus-
host disease (GVHD) prophylaxis to evaluate risk factors and inci-
dence of PTDM in the first 100 days. Prevalence of MS at long-
term followup was assessed.
Methods: Allo-SCT candidates without preexisting DM who met
screening criteria were enrolled. Demographic data and baseline
laboratory data including fasting blood glucose (FBG), lipids, insu-
lin, c-peptide, and fructosamine were collected. PTDM was de-
fined by FBG. 126 mg/dl or random BG. 200. Peak dose and
duration of systemic steroid (SS) treatment for GVHD was col-
lected. MS was defined by NCEP ATPIII criteria based on annual
screens.
Results:Median age of pts was 46 years (yrs) (range 21-66). 44 (52%)
were male. Median FBG pre-SCT was 97 (range 79-121). 50 of 84
(60%) pts developed DM at median of 23 days (interquartile range
14.2-33.8) post-transplant. 33 pts completed study to day 100 with-
out PTDM and 1 died before day 100 without PTDM. Age was sim-
ilar regardless of PTDM development. 28 pts (56%) with PTDM
and 16 pts (47%) without PTDMwere exposed to SS prior to reach-
ing endpoints of PTDM or day 100. Pre-transplant c-peptide levels
were higher in pts with PTDM (median 4.45 mg/dL vs 2.55,
p5 0.015). Among pts receiving SS before day 100, pts with
PTDM were more likely to have received. 1 mg/kg/day of SS
(p5 0.002). Median post-transplant followup was 1.5 yrs (range 18
days-3.6 yrs). 45 pts (54%) were screened for MS at their annual
or subsequent visits (17 pts deceased prior to 1 yr post-SCT). Of
the pts for whom long-term metabolic data were collected, 17
(38%) met criteria for MS. Compared to pts who did not develop
MS, these pts were older (56 vs 41.5 yrs, p5 0.005) and had higher
pre-transplant fasting triglyceride levels (177 vs 108 mg/dl,
p5 0.005). Interestingly, GVHD and use of SS were not associated
with development of MS.
Conclusions: Our data suggest that pre-SCT c-peptide predicts
PTDM, while high triglyceride levels and older age associate with
long-termMS.These findingsmay helpwith counseling,monitoring,
and planning interventions to reduce metabolic sequelae after allo-
SCT, which contribute to cardiac complications in young patients af-
ter allo-SCT.17
AUGMENTATION OF HEMATOPOIETIC ENGRAFTMENT WITHOUT GRAFT
VERSUS HOST DISEASE BY ‘‘ADD-BACK’’ OF PHOTOCHEMICALLY
TREATED T LYMPHOCYTES IN MISMATCHED CORD BLOOD TRANSPLAN-
TATION
Kanathezhath, B.1,2, Neumayr, L.1, Guo, H.1, Walters, M.C.1,
Kuypers, F.A.2 1Children’s Hospital & Research Center, Oakland, CA;
2Children’s Hospital Oakland Research Institute, Oakland, CA
Introduction: Unrelated cord blood transplantation (CBT) is asso-
ciated with a risk of graft rejection due in part to a limiting cellular
content of the CB unit.We have investigated the co-infusion of pho-
tochemically (psoralen S59) treated mature donor T lymphocytes in
a major histocompatibility complex (MHC) [H2-haplotype] mis-
matched murine transplant model as a new method to facilitate en-
graftment of donor CB cells.
Methods: We analyzed the rates of donor hematopoietic cell en-
graftment, graft versus host disease (GVHD), and long-term survival
in H2 haplotype disparate [C57BL/6 (H2Kk/Thy1.1)/AKR
(H2Kb/Thy1.2)] mice after CBT. Three different experimental
groups were transplanted after sublethal radiation. Group 1 received
allogeneic full term newborn peripheral blood alone, group 2 was
transplanted with the same donor cells and unmanipulated donor
T cells, and group 3 was transplanted with the similar donor cells
and psoralen (S-59) treated donor T cells.
Results:We observed a low rate of donor engraftment after trans-
plantation with cord blood alone (Group 1). The best results were
observed after transplantation with 3 x 106 nucleated cord blood
cells and 9 x106 S-59 treated T cells (Group 3b)(p5 0.007).
The engraftment rate was 75% compared to 12.5% after trans-
plantation with 6 x 106 CB cells alone (p5 0.04). The long-
term survival in group 3 was 100% and the rate and severity of
Transplantation Data
Treatment Group CB dose (x 10*6) T-cell dose (x 10*6) GVHD (score 1-10) Engraftment Survival
1 (CB alone) 0.5 - 10 - 1/37 (3) 1/37 (2.7%) 36/37 (97%)
2 (CB1 T) 1.0 – 3.0 3.0 3/8 (6) 3/8 (38%) 4/8 (50%)
3a (CB1 S59 T) 0.5 – 3.0 1.0 – 3.0 0/16 1/16 (6.3%) 16/16 (100%)
3b (CB1 S59 T) 3.0 9.0 1/8 (3) 6/8 (75%) 8/8 (100%)
3c (CB1 S59 T) 6.0 3.0 0/6 3/6 (50%) 6/6 (100%)
T- T lymphocyte, CB- Cord blood
Oral Presentations S161GVHD were minimal. Donor MHC high/c-kit+/lineage-/CD34-
stem cells were noted in the recipient bone marrow compartment
(Group3b). Although lineage specific markers for lymphoid,
myeloid and erythroid series were expressed in the host bone mar-
row and spleen mice by day 30, full hematological recovery was
delayed until 50-60 days after CBT. In-vitro mixed lymphocyte re-
action with S-59 treated T cells demonstrated a 6 fold increase in
Foxp3 + CD4 +CD25+ regulatory T cells after 72 hours of co-cul-
ture compared to control (p5 0.0002).
Conclusions: These results show improved cord blood engr-
aftment kinetics across a disparate H2 haplotype by adding pso-
ralen-treated donor T lymphocytes. Co-transplantation of
psoralen treated lymphocytes with CB cells facilitated durable en-
graftment of donor MHC high/c-kit+ cells in the marrow and
splenic compartments with complete but delayed hematopoietic
recovery. The low GVHD risk and excellent long-term survival
observed in this murine model suggests the potential for clinical
application.18
A MARKOV DECISION ANALYSIS OF POST-REMISSION STRATEGIES IN
2029 PATIENTS WITH AML IN FIRST REMISSION (CR1)
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Background: Various prospective trials which employed genetic al-
location of post-remission treatment have been performed to assess
the role of allogeneic hematopoietic cell transplantation (allo-HCT)
in the treatment of AML in CR1. However, it has been difficult to
clearly demonstrate the clinical benefit of allo-HCT in patients
with AML in CR1. A decision analysis with the Markov process is
a flexible and convenient analytical method that tracks the clinical
events that occur after a certain decision with different probabilities
over time. To address the role of allo-HCT for AML in CR1, we
performed a Markov decision analysis using newly collected clinical
data from 2029 patients.
Methods: Probabilities and other outcome data were derived from
a database of adult AML patients that was constructed from case re-
port files collected for this study.We included patients who were di-
agnosed with AML other than M3 between 1999 and 2006, aged 16
to 70 years, and who had achieved CR1 after 1 or 2 courses of induc-
tion chemotherapy. Using the software package TreeAge Pro, we
constructed a Markov decision model that compared 2 strategies:
allo-HCT in CR1 (HCT group) and no allo-HCT in CR1 (CTx
group). Quality-of-life (QOL) adjustments were made by incorpo-
rating time trade-off utilities that were derived from a questionnaire
to 13 physicians. The cycle length between state transitions was set at
3 months.
Results: A total of 2029 patients were eligible for this analysis. The
median age was 50 years, and the median follow-up of the surviving
patients was 4.1 years. The proportions of patients with favorable,
intermediate, unfavorable and unknown cytogenetic risk by
SWOG criteria were 20%, 54%, 17% and 9%, respectively. Thera-pies performed at CR1 were allo-HCT in 494 patients (24%) and
chemotherapy in 1535 patients (76%). Life expectancy of the
HCT group was longer than that of the CTx group (4.96 vs. 4.44
years, Table1). However, quality-adjusted life expectancy of the
HCT group was comparable to that of the CTx group (4.06 vs.
3.98 years). In patients with intermediate-risk or unfavorable-risk
AML, allo-HCT in CR1 was associated with a longer life expectancy
compared to the CTx group, and adjustment for QOL did not
change the preferred decision.
Conclusion: The results indicated that patients with intermediate-
or unfavorable-risk AML have a longer life expectancy and quality-
adjusted life expectancy with a decision of allo-HCT in CR1.
Life Expectancy and QOL-Adjusted Life Expectancy (years)
Allo-HCT in CR1 No Allo-HCT in CR1Life
Expectancy QOL-AdjustedLife
Expectancy QOL-AdjustedTotal 5.09 4.18 4.44 3.97
SWOG
Favorable 5.00 4.13 5.41 4.86
Intermediate 5.38 4.43 4.46 4.01
Unfavorable 4.66 3.74 3.27 2.9119
SECONDARY SYSTEMIC IMMUNOSUPPRESSANTS (SSI) AFTER MYELOA-
BLATIVE HLA MATCHED RELATED AND UNRELATED BONE MARROW
TRANSPLANTATION (BMT) USING HIGH DOSE CYCLOPHOSPHAMIDE
(HICY) AS SOLE GVHD PROPHYLAXIS
Durakovic, N.1, Bolan˜os Meade, J.1, Zahurak, M.2, Kowalski, J.2,
Fuchs, E.J.1, Jones, R.J.1, Luznik, L.1 1Johns Hopkins University, Balti-
more, MD; 2Johns Hopkins University, Baltimore, MD
The optimal approach for GVHD prophylaxis remains uncertain
and novel strategies are needed. It has been argued that, due to sub-
jectivity in scoring clinical signs of GVHD, additional, more objec-
tive endpoints should be used. One ofmore persuasive ones is the use
of SSI beyond the originally planned prophylaxis.We retrospectively
compared the incidence of GVHD and the use of SSI in 139 consec-
utive patients with advanced hematologic malignancies treated on
a phase II trial using HiCy as a single agent prophylaxis of GVHD
following HLA-matched related and unrelated BMT. We hypothe-
sized that use of this prophylactic strategy will promote tolerance
induction, improve the control of GVHD, and thereby decrease
the overall use of SSI. Patients, median age 49 (21-66), of whom
53% were not in remission at the time of transplant, received
HLA-matched related (n5 79) or unrelated (n5 60) BM after mye-
loablative BuCy conditioning. HiCy (50 mg/kg/day) was given on
days +3, and +4 as only planned GVHD prophylaxis. Patients with
acute grade II-IV GVHD were treated with methylprednisolone
1-2.5 mg/kg/day IV as a first line therapy, and those with visceral
GVHD also received calcineurin inhibitors (CNI) or other non-
CNI immunosuppressants. In the competing risk model (death and
graft failure as competing risks), the incidence of acute grade II-IV
and III-IVGVHDby day 200 was 50% and 16%, respectively. Thir-
teen percent of patients who developed acute grade II-IV GVHD
were not treated 15%were treated with steroids alone, 63%with ste-
roids plus a CNI and 9% with steroids plus non CNI-based agents.
Overall cumulative incidence of SSI use was 45%. Median time to
initiation of SSI was 42 (19-142) days and the median duration of
